Putting Americans First: No medicine is more expensive than the one patients can’t access
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the […]
The most notable differences between the pharmaceutical market in the U.S. and those in other countries are not in the prices. They’re in the […]
The One Big Beautiful Bill Act – the “reconciliation bill” being considered by Congress – features policies that are crucial for driving American innovation.
“This is America,” goes the musical refrain of the new Hims & Hers Super Bowl ad for its compounded obesity drugs. But Hims &
What the Hims & Hers Super Bowl commercial gets wrong about innovation… and America Read More »
Biotechnology’s role in enhancing food security while addressing climate change is gaining deserved attention. It is important that we understand the issue clearly. In
Combatting misinformation on biotechnology in food Read More »
This is the fifth in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
Access to health insurance coverage doesn’t always mean patients have access to the health care services and medicines they need. A new poll, commissioned
Access barriers to medicines plague 1 in 3 patients, new poll finds Read More »
This is the fourth in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
This is the third in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
This is the second in a series of Bio.News articles looking at the need for pharmacy benefit manager reform through the lens of the
Putting patients first: Unchecked step therapy puts PBM profits ahead of patient care Read More »
This is the first in a series of Bio.News articles looking at the need for pharmacy benefit manager (PBM) reform through the lens of